Tiziana MS Drug Trial Meets Goals
Tiziana Life Sciences reports its experimental nasal therapy for multiple sclerosis successfully reduced brain inflammation and fatigue in a mid stage trial. The treatment showed a favorable safety profile with no serious side effects reported among participants.
Tiziana Life Sciences slashed brain inflammation by 50 micrograms in a mid-stage multiple sclerosis trial on Monday morning. The experimental nasal treatment also showed a favorable safety profile across United States clinical sites. Investors drove shares up 7% in premarket trading following the data release.
